Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

The proinflammatory LTB4/BLT1 signal axis confers resistance to TGF-β1-induced growth inhibition by targeting Smad3 linker region

BLT1 Mediates Bleomycin-Induced Lung Fibrosis Independently of Neutrophils and CD4+ T Cells

TACE-Mediated Ectodomain Shedding of the Type I TGF-b Receptor Downregulates TGF-b Signaling

Mediatory role of BLT2 in the proliferation of KRAS mutant colorectal cancer cells

Original Protein tyrosine phosphatase PTPN2 regulates TGF- signaling through Smad4 dephosphorylation

PTPN3 Acts As a Tumor Suppressor and Boosts TGF-β Signaling Independent of Its Phosphatase Activity.

LMTK2 switches on canonical TGF-β1 signaling in human bronchial epithelial cells

TACE-Mediated Ectodomain Shedding of the Type I TGF-β Receptor Downregulates TGF-β Signaling

BLT1 in dendritic cells promotes Th1/Th17 differentiation and its deficiency ameliorates TNBS-induced colitis.

TLR4 ligand/H₂O₂ enhances TGF-β1 signaling to induce metastatic potential of non-invasive breast cancer cells by activating non-Smad pathways.

Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling

LTβR Agonism Promotes Anti-Tumor Immune Responses via Modulation of the Tumor Microenvironment

BLT1 Signaling in Epithelial Cells Mediates Allergic Sensitization Via Promotion of IL‐33 Production

Promotion of Myofibroblast Differentiation and Tissue Fibrosis by the Leukotriene B4–Leukotriene B4 Receptor Axis in Systemic Sclerosis

BLT1-dependent Alveolar Recruitment of CD4(+)CD25(+) Foxp3(+) Regulatory T Cells is Important for Resolution of Acute Lung Injury.

Bcl-3 regulates TGF|[beta]| signaling by stabilizing Smad3 during breast cancer pulmonary metastasis

50. Oncogene BCL6 Antagonizes Tumor Suppressor SMAD4 to Cause TGF-β Resistance

Tlr1/Tlr2 Agonist Induces Tumor Regression by Reciprocal Modulation of Effector and Regulatory T Cells

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF-β growth-suppressive signaling in BCR-ABL1-positive leukemia

Regulation of inflammatory response by LINC00346 via miR-25-3p-mediated modulation of the PTEN/PI3K/AKT/NF-κB pathway